- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Venus Remedies is holding its 36th Annual General Meeting to approve its Annual Report for FY 2024-25. The company delivered strong consolidated financial results, with revenue up 7.72% to ₹647.89 crore and net profit significantly rising by 59.05% to ₹45.31 crore. EBITDA grew to ₹84.49 crore, and cash flow from operations substantially increased to ₹86.44 crore. Notably, the company achieved a Zero-Net-Debt position. Operationally, Venus Remedies advanced its R&D in Anti-Microbial Resistance, secured global tenders, and expanded its digital transformation and sustainability initiatives, enhancing operational excellence for shareholders.